Op2lysis
Overview
Op2lysis is a private French biotechnology company focused on developing innovative therapies for neurological disorders caused by blood clots. Specializing in thrombolytic treatments, Op2lysis aims to advance healthcare in acute ischemic stroke through cutting-edge research and development.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Op2lysis in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.